GAINESVILLE - Cyclo Therapeutics, Inc. (NASDAQ:CYTH), a clinical-stage biotechnology company, has announced the issuance of a U.S. patent for their product, Trappsol® Cyclo™, aimed at treating early onset Alzheimer's disease. The patent, granted by the United States Patent and Trademark Office, is titled "Methods for Treating Alzheimer's Disease" and underlines the company's ongoing efforts to develop therapeutic solutions for this condition.
The new patent comes as a significant addition to Cyclo Therapeutics' portfolio, especially as the company is currently conducting a Phase 2b clinical trial with Trappsol® Cyclo™.
This trial is focused on early Alzheimer's disease, following promising results from an Expanded Access program. The patented product has already been designated as an orphan drug in the United States and Europe, and it is also being tested in four formal clinical trials for Niemann-Pick Disease Type C1, a rare genetic disorder.
N. Scott Fine, CEO of Cyclo Therapeutics, expressed the company's commitment to addressing the unmet medical needs of patients and families affected by early onset Alzheimer's disease. The firm believes in the potential of Trappsol® Cyclo™ to meet these needs and continues to strengthen its patent estate surrounding the product.
The company has made clear that this press release contains forward-looking statements, which reflect current expectations about future results and opportunities. However, these statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors that could influence the company's actual results.
Cyclo Therapeutics has outlined its mission to develop life-changing medicines for patients living with disease, and the recent patent grant represents a step forward in its endeavors. As the company moves ahead with its clinical studies and product development, it remains to be seen how this patent will contribute to the treatment landscape for Alzheimer's disease.
This article is based on a press release statement from Cyclo Therapeutics, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.